Lilly To Include Biomarkers In Phase III Evaluation Of Enzastaurin
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm has initiated Phase III trials of the oral serine-threonine kinase inhibitor to treat non-Hodgkin’s lymphoma and glioblastoma.